524 related articles for article (PubMed ID: 10714631)
21. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
[TBL] [Abstract][Full Text] [Related]
22. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J
J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389
[TBL] [Abstract][Full Text] [Related]
23. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose.
Kole AC; Nieweg OE; van Ginkel RJ; Pruim J; Hoekstra HJ; Paans AM; Vaalburg W; Koops HS
Ann Surg Oncol; 1997 Jan; 4(1):57-63. PubMed ID: 8985518
[TBL] [Abstract][Full Text] [Related]
24. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
[TBL] [Abstract][Full Text] [Related]
25. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
[TBL] [Abstract][Full Text] [Related]
26. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
[TBL] [Abstract][Full Text] [Related]
27. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
28. Multiparametric voxel-based analyses of standardized uptake values and apparent diffusion coefficients of soft-tissue tumours with a positron emission tomography/magnetic resonance system: Preliminary results.
Sagiyama K; Watanabe Y; Kamei R; Hong S; Kawanami S; Matsumoto Y; Honda H
Eur Radiol; 2017 Dec; 27(12):5024-5033. PubMed ID: 28639049
[TBL] [Abstract][Full Text] [Related]
29. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
31. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
32. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
33. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
34. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Elashoff D; Chow K; Evilevitch V; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
Clin Cancer Res; 2009 Apr; 15(8):2856-63. PubMed ID: 19351756
[TBL] [Abstract][Full Text] [Related]
37. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
[TBL] [Abstract][Full Text] [Related]
39. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
40. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases.
Charest M; Hickeson M; Lisbona R; Novales-Diaz JA; Derbekyan V; Turcotte RE
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1944-51. PubMed ID: 19593561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]